What is the address of Dr. Olivia Kamoen, neuroloog?

The registered office of Dr. Olivia Kamoen, neuroloog is located at Ravelsbergstraat 70 box 201, 2100 Antwerpen.

Is Dr. Olivia Kamoen, neuroloog still active?

Yes. According to the CBE (4 October 2026) Dr. Olivia Kamoen, neuroloog is active, legal situation “Normale toestand”, started on 22 July 2021.

Is Dr. Olivia Kamoen, neuroloog registered on Peppol?

No, Dr. Olivia Kamoen, neuroloog is currently not registered on the Peppol network.

What is the enterprise number of Dr. Olivia Kamoen, neuroloog?

The enterprise number of Dr. Olivia Kamoen, neuroloog is BE0771621340.

When was Dr. Olivia Kamoen, neuroloog founded?

Dr. Olivia Kamoen, neuroloog was founded on 22 July 2021.

Who are the directors of Dr. Olivia Kamoen, neuroloog?

According to the 2025 annual accounts, the directors of Dr. Olivia Kamoen, neuroloog are: Olivia Kamoen.

Is Dr. Olivia Kamoen, neuroloog a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 July 2021; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Olivia Kamoen, neuroloog make in 2025?

Dr. Olivia Kamoen, neuroloog posted a profit after taxes of € 39,182 in financial year 2025.

What is the revenue of Dr. Olivia Kamoen, neuroloog?

As a small company, Dr. Olivia Kamoen, neuroloog is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 49,301.

Dr. Olivia Kamoen, neuroloog (Private Limited)

Dossier Dr. Olivia Kamoen, neuroloog, printed on 4 October 2026 from databakkes.be/en/0771621340/dr-olivia-kamoen-neuroloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 35 % of short-term debt in 2025; threshold 65 %.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

Dr. Olivia Kamoen, neuroloog from Antwerpen, company number BE0771621340, closed financial year 2025 with a result of € 39,182 after tax. For that financial year Dr. Olivia Kamoen, neuroloog recorded a gross margin of € 49,301 and equity of € 25,227. Compared with financial year 2024, the result moved from € 18,897 to € 39,182. Profitable, and profit is growing. The buffer shrank hard: equity is 81 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Shrank hard

€ 25,227

▼ 81% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 39,182

▲ 107% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 37,230

▲ € 30,873 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 150,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 166

▼ 64% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,615

▼ 54% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 33,418

▲ € 27,318 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 49,075 Gross margin 2022: € 49,075 First fiscal year in the series	€ 65,381 Gross margin 2023: € 65,381 ▲ 33% vs 2022 (€ 49,075) Favourable step	€ 24,637 Gross margin 2024: € 24,637 ▼ 62% vs 2023 (€ 65,381) Unfavourable step	€ 49,301 Gross margin 2025: € 49,301 ▲ 100% vs 2024 (€ 24,637) Favourable step	▲ 100%
Profit after taxes	€ 38,822 Profit after taxes 2022: € 38,822 First fiscal year in the series	€ 52,074 Profit after taxes 2023: € 52,074 ▲ 34% vs 2022 (€ 38,822) Favourable step	€ 18,897 Profit after taxes 2024: € 18,897 ▼ 64% vs 2023 (€ 52,074) Unfavourable step	€ 39,182 Profit after taxes 2025: € 39,182 ▲ 107% vs 2024 (€ 18,897) Favourable step	▲ 107%
Equity	€ 100,073 Equity 2022: € 100,073 First fiscal year in the series	€ 152,148 Equity 2023: € 152,148 ▲ 52% vs 2022 (€ 100,073) Favourable step	€ 136,045 Equity 2024: € 136,045 ▼ 11% vs 2023 (€ 152,148) Unfavourable step	€ 25,227 Equity 2025: € 25,227 ▼ 81% vs 2024 (€ 136,045) Unfavourable step	▼ 81%
Total debts	€ 15,658 Total debts 2022: € 15,658 First fiscal year in the series	€ 18,918 Total debts 2023: € 18,918 ▲ 21% vs 2022 (€ 15,658) Unfavourable step	€ 10,374 Total debts 2024: € 10,374 ▼ 45% vs 2023 (€ 18,918) Favourable step	€ 163,353 Total debts 2025: € 163,353 ▲ € 152,979 vs 2024 (€ 10,374) Unfavourable step	▲ € 152,979
Cash	€ 96,852 Cash 2022: € 96,852 First fiscal year in the series	€ 25,975 Cash 2023: € 25,975 ▼ 73% vs 2022 (€ 96,852) Unfavourable step	€ 6,357 Cash 2024: € 6,357 ▼ 76% vs 2023 (€ 25,975) Unfavourable step	€ 37,230 Cash 2025: € 37,230 ▲ € 30,873 vs 2024 (€ 6,357) Favourable step	▲ € 30,873
Retained profit	€ 98,073 Retained profit 2022: € 98,073 First fiscal year in the series	€ 150,148 Retained profit 2023: € 150,148 ▲ 53% vs 2022 (€ 98,073) Favourable step	€ 134,045 Retained profit 2024: € 134,045 ▼ 11% vs 2023 (€ 150,148) Unfavourable step	€ 23,227 Retained profit 2025: € 23,227 ▼ 83% vs 2024 (€ 134,045) Unfavourable step	▼ 83%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 35,000 Dividend 2024: € 35,000 Unchanged (€ 0) Unchanged	€ 150,000 Dividend 2025: € 150,000 ▲ € 115,000 vs 2024 (€ 35,000) Unchanged	▲ € 115,000
Balance sheet total	€ 115,732 Balance sheet total 2022: € 115,732 First fiscal year in the series	€ 171,066 Balance sheet total 2023: € 171,066 ▲ 48% vs 2022 (€ 115,732) Unchanged	€ 146,419 Balance sheet total 2024: € 146,419 ▼ 14% vs 2023 (€ 171,066) Unchanged	€ 188,580 Balance sheet total 2025: € 188,580 ▲ 29% vs 2024 (€ 146,419) Unchanged	▲ 29%

Key figures of Dr. Olivia Kamoen, neuroloog, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Olivia Kamoen, neuroloog?

What happened at Dr. Olivia Kamoen, neuroloog in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 39,182 (▲ 107% vs 2024). Source: NBB ↗
Jul 22, 2021 New establishment in Antwerpen. KBO
Jul 22, 2021 Start of the company according to the CBE. KBO

In short

From € 38,822 profit in 2022 to € 39,182 profit in 2025.

Paid € 38,135 in corporate taxes since 2022.

Best year ever: 2023, with € 52,074 profit.

Paid out € 185,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Olivia Kamoen, neuroloog? We notify you, reason included.

Follow Dr. Olivia Kamoen, neuroloog

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Olivia Kamoen

Dr. Olivia Kamoen, neuroloog

Behind Dr. Olivia Kamoen, neuroloog is Olivia Kamoen.

See the full network in the app

Directors

According to the 2025 annual accounts

Olivia Kamoen

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Ravelsbergstraat 70 box 201

2100 Antwerpen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Vereniging van Mede-eigenaars van het gebouw te 2100 Antwerpen-Deurne, Ravelsbergstraat 70

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0771.621.340
VAT number: BE 0771.621.340
Registered office: Ravelsbergstraat 70 bus 201, 2100 Antwerpen
Names & denominations: Dr. Olivia Kamoen, neuroloog
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 22 July 2021
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗